Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies

Journal of Virology

Volumn 88, Issue 24, 2014, Pages 14002-14016

  Ingale, Jidnyasa ^a   Tran, Karen ^b   Kong, Leopold ^a   Dey, Barna ^c   McKee, Krisha ^c   Schief, William ^a,b   Kwong, Peter D ^c   Mascola, John R ^c   Wyatt, Richard T ^a,b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b IAVI Neutralizing Antibody Center at TSRI   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCAN DERIVATIVE; GLYCOPROTEIN GP 120; HYPERGLYCOSYLATED CYSTEINE STABILIZED GP120 CORE; HYPERGLYCOSYLATED CYSTEINE STABILIZED GP120 CORE 10G; HYPERGLYCOSYLATED CYSTEINE STABILIZED GP120 CORE 3G; HYPERGLYCOSYLATED CYSTEINE STABILIZED GP120 CORE 6G; HYPERGLYCOSYLATED CYSTEINE STABILIZED GP120 CORE 7G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; N LINKED GLYCAN; NEUTRALIZING ANTIBODY; NEUTRALIZING ANTIBODY 12A12; NEUTRALIZING ANTIBODY 17B; NEUTRALIZING ANTIBODY 3BNC60; NEUTRALIZING ANTIBODY B12; NEUTRALIZING ANTIBODY B13; NEUTRALIZING ANTIBODY B6; NEUTRALIZING ANTIBODY CH103; NEUTRALIZING ANTIBODY F105; NEUTRALIZING ANTIBODY PGV04; NEUTRALIZING ANTIBODY VH1 02 HEAVY CHAIN; NEUTRALIZING ANTIBODY VRC01; NEUTRALIZING ANTIBODY VRC03; UNCLASSIFIED DRUG; GLYCOPROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; POLYSACCHARIDE;

ADSORPTION KINETICS; ANIMAL EXPERIMENT; ANTIBODY COMBINING SITE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN RECOGNITION; ANTIGENICITY; ARTICLE; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS REACTION; CRYSTAL STRUCTURE; EPITOPE MAPPING; FEMALE; GEL MASS SPECTROMETRY; GLYCAN MASKING; GLYCAN MASS SPECTROMETRY; IMMUNOGENICITY; MASS SPECTROMETRY; NONHUMAN; PROTEIN CONFORMATION; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN MODIFICATION; PROTEIN MOTIF; PROTEIN PROCESSING; PROTEIN PURIFICATION; PROTEIN STABILITY; PROTEIN STRUCTURE; STRUCTURE ACTIVITY RELATION; VARIABLE REGION; VIRUS NEUTRALIZATION; ANIMAL; BINDING SITE; BLOOD; CHEMISTRY; GLYCOSYLATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOLOGY; PROCEDURES; RABBIT;

ANIMALS; ANTIBODIES, NEUTRALIZING; BINDING SITES; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; GLYCOPROTEINS; GLYCOSYLATION; HIV ANTIBODIES; HIV ANTIGENS; HIV ENVELOPE PROTEIN GP120; HIV-1; IMMUNIZATION; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MASS SPECTROMETRY; POLYSACCHARIDES; PROTEIN ENGINEERING; RABBITS;

EID: 84911468878     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02614-14     Document Type: Article

References (50)

1. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, Longo NS, McKee K, O'Dell S, Louder MK, Wycuff DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856-861. http://dx.doi.org/10.1126/science.1187659.
2. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW, Sawyer LS, Hendry RM, Dunlop N, Nara PL. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024-1027. http://dx.doi.org/10.1126/science.7973652.
3. Falkowska E, Ramos A, Feng Y, Zhou TQ, Moquin S, Walker LM, Wu XL, Seaman MS, Wrin T, Kwong PD, Wyatt RT, Mascola JR, Poignard P, Burton DR. 2012. PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4. J. Virol. 86:4394-4403. http://dx.doi.org/10.1128/JVI.06973-11.
4. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivasan K, Sodroski J, Moore JP, Katinger H. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70:1100-1108.
5. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289. http://dx.doi.org/10.1126/science.1178746.
6. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD, Koff WC, Wilson IA, Burton DR, Poignard P. 2011. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477:466-470. http://dx.doi.org/10.1038/nature10373.
7. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, Ruker F, Katinger H. 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67:6642-6647.
8. Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, Steindl F, Katinger H. 2001. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 17:1757-1765. http://dx.doi.org/10.1089/08892220152741450.
9. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS, Imamichi H, Bailer RT, Chakrabarti B, Sharma SK, Alam SM, Wang T, Yang Y, Zhang B, Migueles SA, Wyatt R, Haynes BF, Kwong PD, Mascola JR, Connors M. 2012. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491:406-412. http://dx.doi.org/10.1038/nature11544.
10. Nelson JD, Brunel FM, Jensen R, Crooks ET, Cardoso RM, Wang M, Hessell A, Wilson IA, Binley JM, Dawson PE, Burton DR, Zwick MB. 2007. An affinity-enhanced neutralizing antibody against the membraneproximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10. J. Virol. 81:4033-4043. http://dx.doi.org/10.1128/JVI.02588-06.
11. Burton DR, Poignard P, Stanfield RL, Wilson IA. 2012. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 337:183-186. http://dx.doi.org/10.1126/science.1225416.
12. Phogat S, Wyatt R. 2007. Rational modifications of HIV-1 envelope glycoproteins for immunogen design. Curr. Pharm. Des. 13:213-227. http://dx.doi.org/10.2174/138161207779313632.
13. Diskin R, Scheid JF, Marcovecchio PM, West AP, Jr, Klein F, Gao H, Gnanapragasam PN, Abadir A, Seaman MS, Nussenzweig MC, Bjorkman PJ. 2011. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 334:1289-1293. http://dx.doi.org/10.1126/science.1213782.
14. Sundling C, Forsell MN, O'Dell S, Feng Y, Chakrabarti B, Rao SS, Lore K, Mascola JR, Wyatt RT, Douagi I, Karlsson Hedestam GB. 2010. Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates. J. Exp. Med. 207:2003-2017. http://dx.doi.org/10.1084/jem.20100025.
15. Sundling C, Li Y, Huynh N, Poulsen C, Wilson R, O'Dell S, Feng Y, Mascola JR, Wyatt RT, Karlsson Hedestam GB. 2012. High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site. Sci. Transl. Med. 4:142ra196. http://dx.doi.org/10.1126/scitranslmed.3003752.
16. Forsell MN, Schief WR, Wyatt RT. 2009. Immunogenicity of HIV-1 envelope glycoprotein oligomers. Curr. Opin. HIV AIDS 4:380-387. http://dx.doi.org/10.1097/COH.0b013e32832edc19.
17. McCoy LE, Quigley AF, Strokappe NM, Bulmer-Thomas B, Seaman MS, Mortier D, Rutten L, Chander N, Edwards CJ, Ketteler R, Davis D, Verrips T, Weiss RA. 2012. Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization. J. Exp. Med. 209:1091-1103. http://dx.doi.org/10.1084/jem.20112655.
18. Dosenovic P, Chakrabarti B, Soldemo M, Douagi I, Forsell MN, Li Y, Phogat A, Paulie S, Hoxie J, Wyatt RT, Karlsson Hedestam GB. 2009. Selective expansion of HIV-1 envelope glycoprotein-specific B cell subsets recognizing distinct structural elements following immunization. J. Immunol. 183:3373-3382. http://dx.doi.org/10.4049/jimmunol.0900407.
19. Garrity RR, Rimmelzwaan G, Minassian A, Tsai WP, Lin G, de Jong JJ, Goudsmit J, Nara PL. 1997. Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. J. Immunol. 159: 279-289.
20. Dey B, Pancera M, Svehla K, Shu Y, Xiang SH, Vainshtein J, Li Y, Sodroski J, Kwong PD, Mascola JR, Wyatt R. 2007. Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity. J. Virol. 81:5579-5593. http://dx.doi.org/10.1128/JVI.02500-06.
21. Dey B, Svehla K, Xu L, Wycuff D, Zhou T, Voss G, Phogat A, Chakrabarti BK, Li Y, Shaw G, Kwong PD, Nabel GJ, Mascola JR, Wyatt RT. 2009. Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site. PLoS Pathog. 5:e1000445. http://dx.doi.org/10.1371/journal.ppat.1000445.
22. Pancera M, Lebowitz J, Schon A, Zhu P, Freire E, Kwong PD, Roux KH, Sodroski J, Wyatt R. 2005. Soluble mimetics of human immunodeficiency virus type 1 viral spikes produced by replacement of the native trimerization domain with a heterologous trimerization motif: characterization and ligand binding analysis. J. Virol. 79:9954-9969. http://dx.doi.org/10.1128/JVI.79.15.9954-9969.2005.
23. Wyatt R, Sullivan N, Thali M, Repke H, Ho D, Robinson J, Posner M, Sodroski J. 1993. Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. J. Virol. 67:4557-4565.
24. Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, Stanfield RL, Dimitrov DS, Korber B, Sodroski J, Wilson IA, Wyatt R, Kwong PD. 2005. Structure of a V3-containing HIV-1 gp120 core. Science 310:1025-1028. http://dx.doi.org/10.1126/science.1118398.
25. Feng Y, McKee K, Tran K, O'Dell S, Schmidt SD, Phogat A, Forsell MN, Hedestam GBK, Mascola JR, Wyatt RT. 2012. Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site. J. Biol. Chem. 287:5673-5686. http://dx.doi.org/10.1074/jbc.M111.317776.
26. Madani N, Princiotto AM, Schon A, Lalonde J, Feng Y, Freire E, Park J, Courter JR, Jones DM, Robinson J, Liao HX, Moody MA, Permar S, Haynes B, Smith AB, 3rd, Wyatt R, Sodroski J. 2014. CD4-mimetic small molecules sensitize human immunodeficiency virus (HIV-1) to vaccine-elicited antibodies. J. Virol. 88:6542-6555. http://dx.doi.org/10.1128/JVI.00540-14.
27. Pantophlet R, Wilson IA, Burton DR. 2003. Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design. J. Virol. 77:5889-5901. http://dx.doi.org/10.1128/JVI.77.10.5889-5901.2003.
28. Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, Xiang SH, Yang X, Zhang MY, Zwick MB, Arthos J, Burton DR, Dimitrov DS, Sodroski J, Wyatt R, Nabel GJ, Kwong PD. 2007. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445:732-737. http://dx.doi.org/10.1038/nature05580.
29. Li Y, Svehla K, Louder MK, Wycuff D, Phogat S, Tang M, Migueles SA, Wu X, Phogat A, Shaw GM, Connors M, Hoxie J, Mascola JR, Wyatt R. 2009. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J. Virol. 83:1045-1059. http://dx.doi.org/10.1128/JVI.01992-08.
30. Brunger AT. 2007. Version 1.2 of the crystallography and NMR system. Nat. Protoc. 2:2728-2733. http://dx.doi.org/10.1038/nprot.2007.406.
31. Anumula KR, Taylor PB. 1992. A comprehensive procedure for preparation of partially methylated alditol acetates from glycoprotein carbohydrates. Anal. Biochem. 203:101-108. http://dx.doi.org/10.1016/0003-2697(92)90048-C.
32. Chakrabarti BK, Feng Y, Sharma SK, McKee K, Karlsson Hedestam GB, Labranche CC, Montefiori DC, Mascola JR, Wyatt RT. 2013. Robust neutralizing antibodies elicited by HIV-1 JRFL envelope glycoprotein trimers in nonhuman primates. J. Virol. 87:13239-13251. http://dx.doi.org/10.1128/JVI.01247-13.
33. Xiang SH, Kwong PD, Gupta R, Rizzuto CD, Casper DJ, Wyatt R, Wang L, Hendrickson WA, Doyle ML, Sodroski J. 2002. Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein. J. Virol. 76:9888-9899. http://dx.doi.org/10.1128/JVI.76.19.9888-9899.2002.
34. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393: 648-659. http://dx.doi.org/10.1038/31405.
35. Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, Deller MC, Klasse PJ, Burton DR, Sanders RW, Moore JP, Ward AB, Wilson IA. 2013. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 342: 1477-1483. http://dx.doi.org/10.1126/science.1245625.
36. Tran K, Poulsen C, Guenaga J, de Val N, Wilson R, Sundling C, Li Y, Stanfield RL, Wilson IA, Ward AB, Karlsson Hedestam GB, Wyatt RT. 2014. Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign. Proc. Natl. Acad. Sci. U. S. A. 111:E738-E747. http://dx.doi.org/10.1073/pnas.1319512111.
37. Kuhlman B, Dantas G, Ireton GC, Varani G, Stoddard BL, Baker D. 2003. Design of a novel globular protein fold with atomic-level accuracy. Science 302:1364-1368. http://dx.doi.org/10.1126/science.1089427.
38. Chen L, Kwon YD, Zhou T, Wu X, O'Dell S, Cavacini L, Hessell AJ, Pancera M, Tang M, Xu L, Yang ZY, Zhang MY, Arthos J, Burton DR, Dimitrov DS, Nabel GJ, Posner MR, Sodroski J, Wyatt R, Mascola JR, Kwong PD. 2009. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 326:1123-1127. http://dx.doi.org/10.1126/science.1175868.
39. Arthos J, Deen KC, Chaikin MA, Fornwald JA, Sathe G, Sattentau QJ, Clapham PR, Weiss RA, Mcdougal JS, Pietropaolo C, Axel R, Truneh A, Maddon PJ, Sweet RW. 1989. Identification of the residues in human CD4 critical for the binding of HIV. Cell. 57:469-481. http://dx.doi.org/10.1016/0092-8674(89)90922-7.
40. Arthos J, Deen KC, Chaiken MA, Sattentau QJ, Maddon PJ, Axel R, Rosenberg M, Shatzman A, Truneh A, Sweet RW. 1990. Structuralanalysis of the HIV gp120 binding domain of the CD4 receptor. AIDS Res. Hum. Retroviruses 6:118.
41. Sattentau QJ, Arthos J, Deen K, Hanna N, Healey D, Beverley PCL, Sweet R, Truneh A. 1989. Structural-analysis of the human immunodeficiency virus-binding domain of CD4-epitope mapping with sitedirected mutants and anti-idiotypes. J. Exp. Med. 170:1319-1334. http://dx.doi.org/10.1084/jem.170.4.1319.
42. Yang X, Lee J, Mahony EM, Kwong PD, Wyatt R, Sodroski J. 2002. Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J. Virol. 76:4634-4642. http://dx.doi.org/10.1128/JVI.76.9.4634-4642.2002.
43. Navis M, Tran K, Bale S, Phad GE, Guenaga J, Wilson R, Soldemo M, McKee K, Sundling C, Mascola J, Li Y, Wyatt RT, Karlsson Hedestam GB. 2014. HIV-1 receptor binding site-directed antibodies using a VH1-2 gene segment orthologue are activated by env trimer immunization. PLoS Pathog. 10:e1004337. http://dx.doi.org/10.1371/journal.ppat.1004337.
44. Lanning D, Zhu X, Zhai SK, Knight KL. 2000. Development of the antibody repertoire in rabbit: gut-associated lymphoid tissue, microbes, and selection. Immunol. Rev. 175:214-228. http://dx.doi.org/10.1111/j.1600-065X.2000.imr017516.x.
45. Flajnik MF. 2002. Comparative analyses of immunoglobulin genes: surprises and portents. Nat. Rev. Immunol. 2:688-698. http://dx.doi.org/10.1038/nri889.
46. Kwon YD, Finzi A, Wu X, Dogo-Isonagie C, Lee LK, Moore LR, Schmidt SD, Stuckey J, Yang Y, Zhou T, Zhu J, Vicic DA, Debnath AK, Shapiro L, Bewley CA, Mascola JR, Sodroski JG, Kwong PD. 2012. Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proc. Natl. Acad. Sci. U. S. A. 109:5663-5668. http://dx.doi.org/10.1073/pnas.1112391109.
47. Lyumkis D, Julien JP, de Val N, Cupo A, Potter CS, Klasse PJ, Burton DR, Sanders RW, Moore JP, Carragher B, Wilson IA, Ward AB. 2013. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science 342:1484-1490. http://dx.doi.org/10.1126/science.1245627.
48. Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, Wang C, Chen X, Longo NS, Louder M, McKee K, O'Dell S, Perfetto S, Schmidt SD, Shi W, Wu L, Yang Y, Yang ZY, Yang Z, Zhang Z, Bonsignori M, Crump JA, Kapiga SH, Sam NE, Haynes BF, Simek M, Burton DR, Koff WC, Doria-Rose NA, Connors M, Mullikin JC, Nabel GJ, Roederer M, Shapiro L, Kwong PD, Mascola JR. 2011. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333:1593-1602. http://dx.doi.org/10.1126/science.1207532.
49. Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TY, Pietzsch J, Fenyo D, Abadir A, Velinzon K, Hurley A, Myung S, Boulad F, Poignard P, Burton DR, Pereyra F, Ho DD, Walker BD, Seaman MS, Bjorkman PJ, Chait BT, Nussenzweig MC. 2011. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333:1633-1637. http://dx.doi.org/10.1126/science.1207227.
50. Kassa A, Dey AK, Sarkar P, Labranche C, Go EP, Clark DF, Sun Y, Nandi A, Hartog K, Desaire H, Montefiori D, Carfi A, Srivastava IK, Barnett SW. 2013. Stabilizing exposure of conserved epitopes by structure guided insertion of disulfide bond in HIV-1 envelope glycoprotein. PLoS One. 8:e76139. http://dx.doi.org/10.1371/journal.pone.0076139.